Management of Creatinine Increase in CKD Patient on ACE Inhibitor

Introduction to ACE Inhibitor Management

The American College of Cardiology and Kidney Disease: Improving Global Outcomes (KDIGO) recommend continuing the ACE inhibitor if the creatinine rise is ≤30% from baseline and the patient has no volume depletion, as this modest increase is expected, acceptable, and associated with long-term renoprotection 1, 2

Evaluate for reversible causes before considering ACE inhibitor discontinuation, including checking volume status, reviewing concurrent medications, measuring serum potassium, and calculating percentage creatinine change 3, 4, 1, 6
The European Society of Cardiology recommends checking volume status to assess for dehydration, excessive diuresis, or recent gastrointestinal losses that could cause prerenal azotemia 3, 4
Review concurrent medications to identify nephrotoxic drugs and potassium-altering agents, as recommended by the European Heart Journal 3, 5
Measure serum potassium to check for hyperkalemia, which requires intervention if >5.5 mmol/L, according to the European Heart Journal 3, 1

If creatinine rise is ≤30% from baseline, continue ACE inhibitor at current dose, as this degree of increase is expected and associated with long-term renal protection, recommends Kidney International 1, 2
If creatinine rise is >30% within 4 weeks, reduce ACE inhibitor dose by 50% and recheck labs in 1 week, as suggested by the European Heart Journal 3, 1
If creatinine continues rising or reaches >3.5 mg/dL, discontinue ACE inhibitor immediately, according to the European Heart Journal 3

If potassium is 5.5-6.0 mmol/L, reduce or stop potassium supplements and potassium-sparing diuretics, and add or increase loop or thiazide diuretics to promote potassium excretion, recommends the European Heart Journal and Kidney International 3, 5, 1
If potassium is >6.0 mmol/L, stop ACE inhibitor immediately and monitor blood chemistry closely, and initiate acute hyperkalemia treatment per standard protocols, according to the European Heart Journal and Kidney International 3, 5, 8

Recheck creatinine and potassium in 1-2 weeks to ensure stabilization, then at 1 month, 3 months, and 6 months if stable, recommends Kidney International and the European Heart Journal 1, 2, 3
For patients with eGFR <30 mL/min/1.73 m², monitor every 1-3 months, as suggested by Diabetes Care 7

For diabetic CKD patients with eGFR ≥20 mL/min/1.73 m², add SGLT2 inhibitor while continuing ACE inhibitor for additive renoprotection, recommends Kidney International and Diabetes Care 1, 7
For patients with eGFR <15 mL/min/1.73 m², consider reducing or discontinuing ACE inhibitor if uremic symptoms develop, but continuation is reasonable if well-tolerated, according to Kidney International and Praxis Medical Insights 1, 8